Jacobson Mark L.'s Form 4 filing
Axsome Therapeutics, Inc.AXSM · filed May 29, 2024
- Accession no.
- 0000950170-24-066177
- Filed
- May 29, 2024
- Trade date
- May 29, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $587.8K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Jacobson Mark L.CIK 0001805812 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 29, 2024 | Common Stock | MOption exerciseAcquired | +13,693 | $1.30 | +$17,800.9 | 13,693 | Direct | |
| May 29, 2024 | Common Stock | SSaleDisposed | −7,910 | $74.31F3 | −$587,792.1 | 5,783 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 29, 2024 | Common Stock | MOption exerciseDisposed | −13,693 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $73.99 and $74.52.
Referenced by the price of 1 transaction in Table I.